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Recent benchmark studies have demonstrated the
difficulties in obtaining accurate predictions of ligand
binding conformations to comparative models of
G-protein-coupled receptors. We have developed a
data-driven optimization protocol, which integrates
mutational data and structural information from
multiple X-ray receptor structures in combination
with a fully flexible ligand docking protocol to deter-
mine the binding conformation of AR231453, a
small-molecule agonist, in the GPR119 receptor.
Resulting models converge to one conformation
that explains the majority of data from mutation
studies and is consistent with the structure-activ-
ity relationship for a large number of AR231453
analogs. Another key property of the refined models
is their success in separating active ligands from
decoys in a large-scale virtual screening. These
results demonstrate that mutation-guided receptor
modeling can provide predictions of practical value
for describing receptor-ligand interactions and
drug discovery.
INTRODUCTION
Proteins of the G-protein-coupled receptor (GPCR) superfamily
regulate a broad range of physiological processes (Ritter and
Hall, 2009) and present attractive targets for drug discovery in
multiple therapeutic areas (Wise et al., 2002). Over the past
few years more than 20 distinct GPCRs have been crystallized
with a number of small-molecule antagonists, agonists, and a
G protein (Katritch et al., 2013; Rasmussen et al., 2011; Stevens
et al., 2013). Whereas the drug discovery process greatly bene-
fits from analysis of the structures of target receptors and their
interactions with ligands (Carlsson et al., 2010, 2011; Katritch
et al., 2010a; Kolb et al., 2009), this process has been limited
on targets lacking structural information.Structure 23, 2377–23Even with the increase in structural information, recent
assessment and benchmark studies of GPCR structure
modeling and ligand docking methodologies have demon-
strated widespread difficulty in predicting native ligand binding
conformations to comparative GPCR models (Kufareva et al.,
2011, 2014; Michino et al., 2009; Nguyen et al., 2013). This is
due to the intrinsic flexibility of the seven transmembrane helices
(Deupi and Kobilka, 2010), water-filled pockets (Katritch et al.,
2013), and the involvement of extracellular loops in ligand bind-
ing (Beuming and Sherman, 2012; De Graaf et al., 2008; Shi and
Javitch, 2004). In general, accurate predictions were only
achieved when models were built on related template structures
(sequence similarity >35%) (Katritch et al., 2010a). With an esti-
mated >360 pharmaceutically relevant GPCRs in the human
genome (Vassilatis et al., 2003), it is anticipated that only up to
15% of the GPCR family can be reliably modeled based on the
current distinct experimental GPCR structures, signifying the
need for improved modeling methodologies for receptor targets
lacking closely related template structures.
Realizing these challenges, data-drivenmethods, which incor-
porate experimental information such as ligand structure-activity
relationships (SAR) (Katritch et al., 2010b), multiple template
structures (Kneissl et al., 2009), or mutational data (Michino
et al., 2009) have been proposed to guide the modeling and
refinement of receptor-ligand complexes.
In this study, we have developed a novel mutation-guided
docking protocol that uses the RosettaLigand docking protocol
(Kaufmann and Meiler, 2012; Lemmon and Meiler, 2011) with full
ligand and receptor flexibility in combination with experimental
data to guide the modeling and refinement of receptor-ligand
complexes. The protocol integrates (1) structural information
from multiple distinct high-resolution X-ray structures to create
a knowledge-based ensemble of receptor-ligand complexes
that captures the intrinsic flexibility of the known crystal struc-
tures, and (2) a large experimental library of mutated receptor
variants to guide and enhance the selection of native-like recep-
tor-ligand complexes based on correlations between predicted
binding energies and experimentally determined potency shifts
for all receptor variants.
We applied this method to refine models of the proto-
type agonist AR231453 (Figure 1) in complex with the86, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2377
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Figure 1. Chemical Structure of the GPR119 Agonist, AR231453, and
a Helical Wheel Diagram of the Human GPR119 Receptor
ECL2b contains residues C-terminal to the cysteine in ECL2. Mutated residue
positions and the effect on ligand potency as determined in a cAMP assay (fold
change) are colored gray <5; 5% yellow < 10; 10% orange < 20;R20 red.G-protein-coupled receptor 119 (GPR119), a lipid-responsive
class A receptor (Fredriksson et al., 2003). GPR119 has received
significant interest as a target for the treatment of type 2 diabetes
(Chu et al., 2007, 2008, 2010; Fyfe et al., 2008), with small-mole-
cule agonists (e.g. AR231453) reported to promote pancreatic
postprandial insulin and incretin secretion in a glucose-depen-
dent fashion (Semple et al., 2011). In a previous study we applied
classical docking methods to elucidate the binding mode of
AR231453 to GPR119, but were unable to discriminate between
multiple possible binding conformations (Engelstoft et al., 2014).
In this study we find a strong correlation around one binding
conformation, which explains the majority of the mutations and
is inagreementwithSAR for a largenumberofAR231453analogs.
Interestingly the mutation-guided models, in contrast to simple
homologymodels, proved successful in separating active ligands
fromdecoys in a large-scale retrospective structure-based virtual
ligand screening. This method of integrating experimental data
in combination with fully flexible receptor-ligand docking simula-
tions may serve as an important tool for structure-function anal-
ysis and guide the discovery of novel active chemotypes.
RESULTS
Modeling of the AR231453 GPR119 Receptor Complex
Full-length models of the human GPR119 receptor were gener-
ated using a multi-template approach by combining fragment
replacement and structural restraints from multiple GPCR
X-ray structures (see Supplemental Information). To account
for the substantial structural variability of ligand binding pocket
conformations in distinct GPCR crystal structures, we produced
a number of energetically feasible receptor conformations by
minimizing the energy of the backbone and side chains using
the Rosetta relax protocol and the membrane force field (Barth
et al., 2007; Leaver-Fay et al., 2011). Subsequent clustering
based on binding site residues in contact with ligands in the
template structures was used to generate a non-redundant
low-energy ensemble of 43 receptor models, which were used
as input in the docking simulations to broadly sample the binding
pocket geometry.2378 Structure 23, 2377–2386, December 1, 2015 ª2015 Elsevier LtdA conformational ensemble of low-energy structures of
AR231453 (see Supplemental Information) was docked into the
receptor ensemble using the RosettaLigand docking protocol
that samples both receptor and ligand flexibility (Kaufmann
and Meiler, 2012; Lemmon and Meiler, 2011). A total of 43,000
receptor-ligand complexes were generated to extensively sam-
ple receptor-ligand binding conformations. To ensure that re-
ceptor flexibility of the binding pocket was sampled within the
structural variations observed in the experimental structures,
we discarded conformations in which Ca atoms of binding
pocket residues deviated by more than four standard deviations
from the variation in the corresponding Ca atom positions in 16
distinct experimental GPCR structures (see Supplemental Infor-
mation and Figure S2). The tolerated structural variability is illus-
trated in Figure 2A, which shows that some helices, especially
the top of transmembrane helix (TM-II), can assume several
different orientations, while others are more static.
Docking Simulations Converge to Two Binding
Orientations
To analyze the ligand binding space we measured the distance
from the sulfonyl moiety to the bottom of the binding pocket,
and the distance of the isopropyl group to the loop region in
the 43,000 generated receptor-ligand complexes. The ligands
in this ensemble assumed widely different binding conforma-
tions, as illustrated by the 100 randomly selected ligand orienta-
tions shown in gray in Figure 2B.
Ligand interaction energies were applied to reject loosely
packed binding conformations expected to be biologically irrel-
evant. We examined the resulting ensemble by analyzing the ten
most frequently occurring binding conformations. This revealed
two major ligand binding orientations, one in which the sulfonyl
group is in the loop region (SO2-out, illustrated in Figure 2B)
and the other where the ligand is flipped 180 so that the sulfonyl
is in the bottom of the binding site (SO2-in). Within each orien-
tation multiple conformations were seen. The frequency and
computed ligand binding energy of the two binding orientations
were similar. From the models alone it was difficult to discrimi-
nate between the two binding orientations, indicating that flexi-
bility filters alone are not sufficient to reach convergence.
Integration of Mutational Mapping Data Exhibits
Preference for One of the Binding Conformations
To further improve convergence of the predicted receptor-ligand
complexes, we developed a mutation-guided optimization pro-
tocol that correlates the binding affinity associated with a library
of GPR119 mutations with the computationally estimated bind-
ing energies. The analysis included 33 non-glycine, non-proline,
single-point mutations located in the ligand binding pocket (Fig-
ure 1 and Table 1).
The ligand binding energy associated with each mutation
would ideally be determined by measuring KD in a ligand binding
assay. However, since direct ligand binding assays are currently
unavailable for GPR119 we instead used a cyclic AMP (cAMP)
assay to determine the potency (EC50). By assuming a constant
mutation-independent relationship between KD and EC50, it is
anticipated that potency shifts provide a good surrogate mea-
sure of relative binding energies and correlation-based score.
However, this relationship might be different when receptorAll rights reserved
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Figure 2. Restricted Sampling of Receptor Flexibility Together with Mutation-Guided Methods Converges to One Major Binding Conforma-
tion of AR231453 to GPR119
(A) Biologically irrelevant receptor conformations were removed by filtering the generated GPR119/AR231453 ensemble using residue-specific limits for de-
viations from known GPCR crystal structures (see Supplemental Information). These limits of flexibility are illustrated as spheres on the b2-adrenergic receptor.
(B) In contrast to the filtered ensemble (green arrows with golden heads), the unfiltered ensemble yielded no strong preference for a particular binding
conformation (gray arrows with blue heads). The arrowhead points to the sulfonyl (S atom) of the ligand, while the tail is at the isopropyl moiety. A subset of
mutated residues are shown as sticks and colored according to potency shift upon mutation (Figure 1).
(C–E) To further remove biologically irrelevant binding conformations, we mapped the binding space based on the ligand orientation as a function of computed
interaction energy (Rosetta Energy Units) and the correlation coefficient between experimental and computational binding energy. The ligand orientation was
described as SO2-out when the sulfonyl group (arrowhead) was pointing to the extracellular side. Structures in the best-scoring quadrant (red dashed square in C)
and the SO2-out were both enriched with respect to frequency of sampling (D), and achieved higher correlation coefficients compared than the SO2-in
conformation (E).
See also Figures S2 and S3.expression is compromised, and on this behalf we excluded four
variants (165Phe5.38Leu V:04, 165Phe5.38Ala V:04, 174Phe5.49Ala
V:13, and 154GlnECL2Ala 11) that decrease expression level to
less than 20% of the wild-type receptor (residues are numbered
according to the GPCR numbering system of Schwartz et al.,
1995 and Ballesteros and Weinstein, 1995). Mutations that alter
the functional integrity of the receptor, for example by disallow-
ing the active state, would also lead to misinterpretation. To
account for this we discarded one variant (238Trp6.48Ala VI:13)Structure 23, 2377–23with no constitutive activity that could not be activated by
the ligand. In addition we discarded one variant (81Arg3.27Ala
III:03) that was not in the ligand binding pocket. This left us
with a set of 28 GPR119 variants. The strongest decrease in re-
ceptor activation was observed for themutated residues located
in the extracellular segments of TM-III, -V, -VI, and -VII, as well as
in ECL2 and ECL3, as illustrated in Figure 1.
For each of the 43,000 receptor-ligand models we then
computed the Spearman correlation coefficient (SCC) between86, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2379
Table 1. GPR119 Mutagenesis Data for AR231453
GPR119 Variant
Surface Expression Basal Activity Max. Efficacy AR231453 EC50
Potency Shift n Assay% SEM % SEM % SEM Log SEM nM
Wild-type 100 0.9 37 0.7 100 0.9 8.73 0.03 1.9 26 A
Wild-type 100 0 56.5 1.8 99.4 1.9 8.74 0.34 1.9 9 H
Binding Pocket
61Leu2.60Arg II:20* 29 4.4 30 5.1 70 5.2 8.62 0.61 2.4 1 3 H
65Gln2.64Ala II:24* 122 9.4 31 5.3 99 7.1 8.9 0.24 1.2 1 4 A
81Arg3.28Ala III:04 51 2.4 1.9 1.5 41 2.5 7.94 0.15 11.6 6 4 A
82Met3.29Ala III:05* 78 5.8 8.3 1.4 24 1.9 8.37 0.19 4.3 2 4 A
85Val3.32Ala III:08* 115 9.2 29 6 88 7.2 8.8 0.28 1.6 1 4 A
86Thr3.33Ala III:09* 55 12 13 2.1 39 4.5 7.8 0.36 15.8 8 4 A
86Thr3.33Val III:09* 71 14 32 7.2 61 6.2 8.9 0.63 1.3 1 4 A
89Ala3.36Val III:12* 231 43 27 6 90 32 6.99 0.81 103 54 4 A
162His5.35Ala V:01* 58 4.3 20 1.9 73 2.4 8.75 0.08 1.8 1 3 A
165Phe5.38Ala V:04 2 2 8 1.8 28 2.9 7.84 0.58 14 7 3 H
165Phe5.38Leu V:04 7 3 7.6 2.4 27 3.1 8.34 0.13 4.6 2 3 H
166Val5.39Ala V:05* 53 9.1 35 6.6 70 8.5 8.03 0.61 9.3 5 3 A
170Ser5.43Ala V:09* 157 17 57 7.5 108 7.4 8.64 0.38 2.3 1 4 A
170Ser5.43Val V:09* 164 30 12 3.5 77 5 8.02 0.16 9.7 5 4 A
174Phe5.47Ala V:13 20 4.5 26 3 53 4.3 8.24 0.18 5.7 3 2 H
238Trp6.48Ala VI:13 40 2.6 – – – – – – >10,000 >5,000 4 A
241Phe6.51Ala VI:16* 72 4.7 11 1.8 27 4.4 7.47 0.5 34 18 3 A
242Leu6.52Ala VI:17* 39 4.9 55 3 103 3.6 8.52 0.08 3 2 3 H
248Gln6.58Ala VI:23* 111 18 31 7.9 87 11 8.07 0.41 8.6 5 3 A
261Glu7.35Ala VII:02* 54 5.1 13 1.3 54 3.3 7.75 0.16 17.7 9 4 A
262Arg7.36Ala VII:03* 50 4.1 0.1 0.7 18 1.2 8.01 0.14 9.8 5 4 A
265Trp7.39Ala VII:06* 40 2.8 34 2.7 – – – – >10,000 >5,000 5 A
ECL2a
Gln11Ala (154) 16 6.3 28 2.7 63 2.8 8.9 0.24 1.3 1 3 H
ECL2b
156Sercys155+1Ala* 71 3.5 6.9 1.3 48 2.2 8.44 0.12 3.7 2 3 A
157Phecys155+2Ala* 69 4.4 6.4 0.5 23 1.7 6.83 0.18 147 77 5 A
158Phecys155+3Ala* 73 3.6 5.1 0.6 24 1.5 7.19 0.13 65 34 5 A
160Valcys155+5Ala* 66 3.4 5.7 0.9 34 1.4 8.13 0.11 7.4 4 3 A
161Phecys155+6Ala* 56 2.3 5.6 1 21 1.2 8.65 0.15 2.2 1 3 A
ECL3
252Gln6.62Ala* 51 6.4 49 8.8 83 9.9 8.69 0.46 2.1 1 3 H
253Glu6,63Ala* 31 5.9 48 4.8 99 5.5 8.7 0.18 2 1 3 H
255His6.64Ala* 43 10.4 33 4.2 76 4.7 8.76 0.13 1.7 1 3 H
256Leu6.65Ala* 44 14.8 54 2 96 6 7.19 0.35 65 34 4 H
258Leu6.67Ala* 48 7.5 44 6.3 96 7.6 8.52 0.18 3 2 3 H
Surface expression, basal activity, efficacy, potency, and potency fold change for wild-type human GPR119 and receptor mutants. Residues used for
correlation analysis are marked by an asterisk. Two assays were used: Alumnia (A) and Hithunter (H). We described data derived from the Alumnia
assay in a previous study (Engelstoft et al., 2014).the computationally predicted and experimentally estimated
binding energies for each of the 28 mutated receptor variants.
The density of ligand binding orientation as a function of interac-
tion energy and correlation coefficient for the generated complex
ensemble is shown in Figure 2C.
We note that despite the exclusion of mutations with
decreased expression level or lack of constitutive activity, a2380 Structure 23, 2377–2386, December 1, 2015 ª2015 Elsevier Ltdstrong correlation between experimental potency shifts and
computational binding energies cannot be expected due to the
inherent approximations of themeasure. Therefore, when further
analyzing the structures we applied a conservative correlation
cutoff of 0.25, while taking the 10%most energetically favorable
models and discarding all structures violating the allowed
backbone flexibility (Figure 2D). Clustering the resulting 207All rights reserved
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Figure 3. The Mutational Data and SAR
Support the Refined Ligand Binding
Conformation
(A) The predicted binding mode of AR231453 is
consistent with the SAR of ligands. The most likely
GPR119/AR231453 complex with residues are
colored according to potency shift on AR231453
upon mutation (gray <5; 5 % yellow < 10; 10 %
orange < 20; R20 red). The sulfonyl group is situ-
ated in the extracellular part of the receptor, with
room for large substitutions, which only have a mi-
nor effect on ligand potency. Conversely, sub-
stitutions are not tolerated at the bottom of the
binding pocket, which packs tightly around the
ligand. The surface of the binding pocket is colored
according to the potency shift of the nearest res-
idue.
(B) Ligplot of predicted AR231453 GPR119 in-
teractions (Table 1). AR231453 is predominantly
in contact with residues affecting the potency
upon mutation. Mutations that did not affect the
potency of AR231453 (gray) could in most cases be
explained by their remote position relative
to AR231453 in the models. The isopropyl-ox-
adiazole moiety is involved in H-bond interactions
with 86Thr3.33 III:09, 170Ser5.42 V:09.
(C) The chemical moieties responsible for the
distinct pharmacology of AR437735 (agonist)
and AR437948 (inverse agonist) mimic the common
oxadiazole moiety found in many GPR119 agonists
(green shaded area), predicted to be involved
in different interactions with 86Thr3.33 III:09,
170Ser5.42 V:09.
See also Figure S4.structures with a clustering radius of 2.5 A˚ root-mean-square
deviation (RMSD) for the ligand position resulted in 73 clusters.
The ten most populated clusters were strongly preferred and
numbered approximately half of the structures. Among these,
95% of the models were in the SO2-out binding conformation
(Figure 2B, green arrows), which also had a better binding energy
score and higher correlation coefficients with the experimental
data than the SO2-in binding conformation (Figure 2E). Repre-
sentative low-energy models with high SCC scores from the
five most populated binding modes all shared the SO2-out
binding conformation (Figure S3). Corresponding PDB files of
the complexes are provided in the Supplemental Information.
Mutagenesis Data and Ligand SAR Support Predicted
Binding Modes of AR231453 in GPR119
Due to the inherent inaccuracy of the force field and the use of
potency shifts as a proxy for the actual binding energy, it is un-
clear whether any of the models would have atomic accuracy,
and we do indeed see variations between the different clusters
in the SO2-out conformation. The structures from the largest
clusters do, however, generally occupy the same binding pocket
surrounded by key residues situated at helices II, V, VI, VII, and
the extracellular loops.
Figure 3 shows a representative binding conformation from
the largest cluster where the ligand forms very few contacts to
residues not affecting ligand potency, but forms contacts to
all residues affecting ligand potency by more than 20-fold. TheStructure 23, 2377–23two phenylalanines of ECL2 (157FCys155+2 and 158FCys155+3)
and the leucine of ECL3 (L256A) pack tightly around the 2-flu-
oro-4-methanesulfonyl-phenyl moiety, but leaves the methyl
group exposed. This is consistent with ligand SAR previously
reported by Semple et al. (2008), who showed that large substi-
tutions can be made to the methyl moiety without dramatic
effects on ligand potency (Figure 3). Notably, this SAR further
validates the SO2-out binding conformation in contrast to the
SO2-in, which is incompatible with large substitutions at the
SO2 group.
The 5-nitro-pyrimidine core at the middle of the ligand is
loosely packed at the binding pocket in contrast to the 4-meth-
anesulfonylphenyl and oxadiazole termini (see below), which
appear to be more tightly bound. Looking across the largest
clusters we see some variation in the exact location of this group.
In many cases, it is packed against a phenylalanine (241Phe6.51
VI:16) and a tryptophan (265Trp7.39 VII:06), with the nitro group
exposed to a water-filled cavity. In the most common binding
conformation, the aniline linker makes H-bond donor interac-
tions with the glutamate (261Glu7.35 VII:02), supporting a 9-fold
change in ligand potency upon mutation to alanine. In other
clusters 261Glu7.35 VII:02 is involved in internal residue-residue
interactions with the spatial nearby residues 248Gln6.58 VI:23
and 262Arg7.36 VII:03, which moderately affects potency when
mutated to alanine. The loose packing of the 5-nitro-pyrimidine
core is also to be expected, as many GPR119 agonists
differ greatly in their middle portions (Table S1), while the end86, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2381
Initial homology models                    AUC         EF(1%)      EF(10%)
1.   Raw homology model (A2aAR template)  0.54 0.46 1.38
2.   Hybrid GPR119 model   0.54 0.92 1.38
3.   Refined model (Rosetta relax)  0.43 1.35 0.72
Best performing mutation guided models 
4.   Mutation guided model (cluster 7) 0.85 26.0 6.18
5.   Mutation guided model (cluster 2) 0.83 36.8 6.28
6.   Mutation guided model (cluster 8) 0.80 17.0 5.25
7.   Mutation guided model (cluster 1) 0.78 25.6 5.29
8.   Mutation guided model (cluster 1) 0.78 22.9 5.38
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Figure 4. Refined Receptor Models Enrichment of Active Com-
pounds in an In Silico Screen
(A) Percentage of recovered actives as function of screened compounds is
shown for models from different stages of the protocol. The initial homology
models (gray) had a lower docking performance compared with the five
best-performing models (red and green) derived from the mutation-guided
optimization protocol. Inset shows a normal view of the ROC curves. The false-
positive rate as a function of screened compounds is shown on a logarithmic
scale to highlight the initial enrichment at 1% of the dataset.
(B) Summary of key characteristics of the corresponding ROC curves and
virtual screening performance.
See also Table S1.termini are often the same—namely a methanesulfonyl at one
end, and an aminooxadiazole or carbamate at the other.
Because these polar side chains have the ability to both make
H-bond interactions with each other and/or a ligand, the models
in the largest clusters support the binding of different 5-nitro-
pyrimidine substitutions of, for example, the nitro group and an
N/O/CH2 linker.
The oxadiazole moiety is located at the bottom of the bind-
ing pocket surrounded by 170Ser5.31 V:09, 86Thr3.33 III:09, and
89Ala3.36 III:12. The mutational data suggest that there is limited
space available, as a mutation of alanine to valine results in a
50-fold decrease of potency. This behavior is also consistent
with ligand SAR, which allows limited extension of the isopropyl
group, consistent with a small pocket that can be recognized
in some of the models, but disallows larger substitutions.
Again, ligand SAR favors the SO2-out conformation over the
SO2-in.2382 Structure 23, 2377–2386, December 1, 2015 ª2015 Elsevier LtdRelated Binding Conformation of an Agonist and an
Inverse Agonist
In the optimization process of pharmacologically attractive
GPR119 agonists, we identified ligands for which single
atom substitutions could change the efficacy from agonist
(AR437735) to inverse agonist (AR437948) (Figures 3C and S4;
Supplemental Information). The models and the similarity of
the ligands with AR231453 suggest that they bind in a similar
fashion as AR231453 (Figure 3B). The chemical moieties
responsible for the distinct pharmacology mimics the common
oxadiazole moiety found in many GPR119 agonists (Semple
et al., 2011), predicted to be involved in interactions with
86Thr3.33 III:09 and 170Ser5.42 V:09. That the activity of the
ligand can be modulated with a thioester/thionoester substitu-
tion is perhaps not entirely surprising, as the energy difference
between active and inactive states must be fairly small in
GPR119 since it is a constitutively active receptor. It could
thus be possible that the minor difference in H-bond acceptor
properties between the two ligands is sufficient to stabilize
two different conformations. Another possibility is that the
ligands adopt different conformations in the receptor. Indeed,
a conformational analysis reveals that both ligands are isoener-
getic (<0.1 kcal/mol) with respect to having the thioester/
thionoester axial or equatorial to the piperidine ring. A similar
conformation-based hypothesis has also been proposed by
McClure et al. (2011) to describe the agonist response of a
related GPR119 agonist.
Mutation-Guided Receptor-Ligand Models Dramatically
Improve Virtual Screening Performance Related to Drug
Discovery Applications
To further validate the GPR119 models, we evaluated their per-
formance in virtual ligand screening for their ability to discrimi-
nate known actives from decoys. We created a library of 223
known GPR119 active ligands (Table S1) extracted from
ChEMBL (Gaulton et al., 2012) and 91,712 screening com-
pounds (decoys) with similar molecular property distribution as
active compounds extracted from vendor databases (see Sup-
plemental Information). We identified the five best-performing
models from the ten largest clusters in terms of active compound
scoring with SurflexDock (Jain, 2003). Active and decoy com-
pounds were then docked against those fivemodels. The perfor-
mance was evaluated based on the percentage of recovered
active compounds, the corresponding area under the receiver-
operating characteristic (ROC) curve (AUC), and the computed
enrichment factors (EF) for the top 1% and 10% ranked com-
pounds. Only suboptimal docking performance and low selec-
tivity of known active compounds (AUC = 0.54, EF1% = 0.5,
EF10% = 1.4) were achieved for the initial homology model based
on the closest related A2aAR template structure (Figure 4).
Equally low selectivity (AUC = 0.54, EF1% = 0.9, EF10% = 1.4)
was found for the hybrid homology model. The ensemble of
relaxed models used as input in the docking simulations all per-
formed worse than random and revealed poor docking scores of
actives as well as decoys. This might be related to a partial
collapse of the ligand binding pocket as a result of the initial re-
ceptor optimization in the absence of a ligand, and provides a
warning against the use of simple homology models or relaxed
homology models in in silico screening.All rights reserved
In contrast, the models developed through the mutation-
guided docking protocol demonstrated a dramatic improve-
ment in virtual screening performance compared with the initial
homology models and random baseline (Figures 4 and S4). The
five best-performing models represented members of some of
the largest clusters and were all in the SO2-out binding orienta-
tion. The overall best-performing model demonstrated good vir-
tual screening performance (AUC = 0.85) and early enrichment
(EF1% = 26.0 and EF10% = 6.18). The second best-performing
model (AUC = 0.83), representing the second most populated
docking mode, was especially efficient in respect of initial
enrichment (EF1% = 36.8). Good initial enrichment (EF1% =
25.6) was also achieved for the most populated binding
mode. In comparison, the best SO2-in model had a poor
screening performance (AUC = 0.65) and early enrichment
(EF1% = 13.9). Notably, these screening performances are com-
parable with the virtual screening performance that can be ex-
pected from a high-resolution crystal structure (Spitzer and
Jain, 2012), suggesting that the mutation-guided models might
be valuable in virtual screening applications aimed at identifying
novel active chemotypes. Indeed, among the top 1% scoring
compounds the virtual screening did not only enrich for agonists
similar to AR231453, but also identified active compounds lack-
ing the preferred sulfonyl and oxadiazole moiety. For instance,
across all models described in Figure 4, 13% of the hits had
both features, 75% had only one of them, and the last 12%
had none. In comparison, the full dataset of active compounds
contained 8% with both, 54% with only one, and 38% missing
both.
DISCUSSION
This study shows that mutagenesis data can be used in a sys-
tematic and unbiased way to counter the poor force field perfor-
mance of GPCR/small-molecule docking, and thus generate
models in agreement with ligand SAR and of sufficient quality
to support structure-based drug design. In this work we specif-
ically focused on the GPR119 receptor in complex with a proto-
type agonist.
Themajor challenges in small-molecule docking arise frommi-
nor inaccuracies in structural models due to alignment inaccur-
acies, the lack of explicit water molecules, and inaccuracies of
the force field, combined with the necessity for intensive confor-
mational sampling. These inaccuracies often preclude the use
of energies to reliably discriminate between correct and incor-
rect models (Fleishman and Baker, 2012; Lu et al., 2007). The
problem is even greater for GPCRs, where the receptor itself bal-
ances between discrete substates of active and inactive confor-
mations (Deupi and Kobilka, 2010; Manglik and Kobilka, 2014;
Staus et al., 2014) that, for constitutive active receptors, can
be separated by less than 1 kcal/mol. To counter this challenge,
ligand structure-activity relationship data (Katritch et al., 2010b)
and mutagenesis data (Kufareva et al., 2011; Michino et al.,
2009; Nguyen et al., 2013) can be used to increase the accuracy
of generated receptor-ligand models by complementing the
energy function.
The use of mutagenesis data does, however, pose a problem,
as many residues affect ligand binding indirectly and thus do not
allow for a simple residue-by-residue interpretation (JaakolaStructure 23, 2377–23et al., 2010; Kim et al., 2003). This problem is not widely appre-
ciated in the docking literature, where manual selection of spe-
cific residues for which residue-ligand ‘‘must-have-contact’’
constraints are defined to reject or accept models from ligand
docking ensembles. To avoid this binary approach that is prone
to misinterpretation, we developed an unbiased protocol to
refine and increase the accuracy of a receptor-ligand ensemble
using knowledge-based filters and correlations with a large set of
experimental mutation data in combination with a fully flexible re-
ceptor-ligand docking protocol. The protocol enables an unbi-
ased selection and refinement of models best suited to describe
ligand bound states, which convincingly support the majority of
the mutational mapping.
The generated models cluster around one major binding
conformation, which is coherent with SAR of GPR119 ligands.
Minor extension at the isopropyl-oxadiazole moiety improves
binding affinity by filling out a cavity at the ligand-receptor inter-
face, while larger substitutions result in clashes and are detri-
mental for potency. The other end of the ligand is solvent
exposed and allows for larger substitutions. The models demon-
strate the ability to enrich a broad selection of diverse high-
affinity GPR119 agonists (belonging to several different scaffold
classes not employed in model optimization), supporting the
protocol’s suitability for drug discovery and structure-based
drug design applications.
Comparison of the AR231453 binding conformation in
GPR119 (Figure 3A) to bound ligands in recently solved GPCR
structures suggests that AR231453 occupies a similar position
in the transmembrane domain as agonist bound (e.g. UK-
432097) A2AAR structures (Xu et al., 2011). Analysis of agonist
and antagonist bound A2AAR and b1AR structures suggests
that agonists (in contrast to antagonists) makes distinct interac-
tions with polar residues in the lower part of the binding pocket
(just above the conserved Trp6.48 VI:13) in both A2AAR (Ser
7.42
VII:09 and His7.43 VII:10) (Katritch et al., 2010a; Lebon et al.,
2011a; Xu et al., 2011) and b1AR (Ser5.46 V:12) (Warne et al.,
2011) to promote or stabilize an active receptor state (Dal Ben
et al., 2010; Kim et al., 2003; Lebon et al., 2011b). Interestingly,
the atom substitutions resulting in the efficacy switch from
agonist (AR437735) to inverse agonist (AR437948) occur in the
same area as the residues involved in H-bond interactions
responsible for triggering the agonist response in A2AAR and
b1AR (Figure 3C). At present the extent and duration of activation
of the receptor needed for maximum clinical benefit are not
known. Chemical modification to this portion of the molecule
could prove important for agonist design to identify pharmaco-
logically superior agonists.
To further the use of mutational data in ligand docking, we are
currently developing methods that will allow on-the-fly optimiza-
tion of correlation with experimental data. Likewise, further
development of position-specific backbone constraints for
homology model construction is expected to be useful, not
only for GPCR homology modeling but for flexible backbone
modeling of any structure from a family with multiple solved
structures.
Conclusion
In the absence of a crystal structure, theoretical modeling and
mutagenesis analysis are important tools in characterizing the86, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2383
structural basis of ligand binding. We have developed an unbi-
ased mutation-guided docking protocol in combination with
RosettaLigand to characterize the structural basis for ligand
binding to the GPR119 receptor. This protocol uses intrinsic
flexibility of distinct GPCR crystal structures and correlations
between predicted binding energies and experimentally deter-
mined potency shifts for a large number of mutated receptor
variants. The generated models of ligand binding to GPR119
are consistent with mutational data and SAR, and are sufficiently
accurate to support structure-based design efforts for this
target. Although the current mutation-guided simulation protocol
was limited to GPR119, the protocol can be translated to other
receptors and possibly provide important guidance for GPCR
modeling in general.
EXPERIMENTAL PROCEDURES
Experimental Determination of Binding Potency
AR231453 was synthesized as previously described (Semple et al., 2008).
Synthesis of AR437735 and AR437948 is described in Supplemental Experi-
mental Procedures. The construction of the GPR119 variants and effect of
the mutations on the constitutive and ligand-induced (AR231453) receptor
activation was determined with cAMP accumulation assays in transfected
COS7 cells as described in Supplemental Experimental Procedures. Surface
expression and basal activity of human GPR119 wild-type and receptor mu-
tants along with efficacy and potency of AR231453, as well as the potency
fold change between wild-type and mutants, are listed in Table 1.
Construction of Comparative GPR119 Homology Models
We constructed two GPR119 models assembled by fragments from three
distinct class A GPCRs including the adenosine A2a receptor (PDB: 3EML),
the CXCR4 (PDB: 3ODU) receptor, and the dopamine D3 (PDB: 3PBL) receptor
(Figure S1). Models were constructed using dopamine D3 to model ECL3,
CXCR4 to model ECL2a, and A2a or CXCR4 to model TM IV, while the rest
of the receptor was modeled using A2a. Side chains for all residues were
optimized, and the models were subsequently minimized using 200 steps of
steepest descent and 300 steps of conjugated gradient-energy minimization
as implemented in ICM version 3.7-2 (Molsoft). The initial GPR119 homology
models were refined using Rosetta version 3.2.1. Specifically, the seven initial
homology models were subjected to 1,000 steps of full-atom structure relax-
ation using the membrane force field (Barth et al., 2007). During the relax
protocol, a disulfide bridge between 78Cys3.25 III:01 and 155CysECL2b in the
second extracellular loop was specified. The best 300 (top 30%) scored
models derived from each of the initial structures were clustered with respect
to the RMSD of the residues surrounding the binding pocket, thus selecting 43
major structural low-energy variants.
Unbiased Mutation-Guided Docking of AR231453
A conformational ensemble of AR231453 containing nine conformations within
3 kcal/mol of the global minimumwas generated in ICM version 3.7-2 using the
Merck Molecular Force Field (MMFF) and a generalized Born implicit solvation
model. To extensively sample the ligand binding conformations of AR231453
in a 5-A˚ docking sphere around 265Trp7.39 VII:06 in GPR119, we generated
43,000 complexes with the RosettaLigand XML docking protocol (Davis and
Baker, 2009; Lemmon andMeiler, 2011; Meiler and Baker, 2006). The resulting
models were filtered based on three criteria. First, we discarded the 90%
worst-scoring structures with regard to binding energy. Second, models
were only accepted if all residues lining the pocket did not deviate by more
than four standard deviations from the average Ca coordinate for that position,
as observed in experimental GPCR structures. Third, acknowledging that no
single residue in a one-sided mutational mapping can be safely interpreted
as a ligand-contacting residue, we developed a correlation-based scoring
scheme (Figure S3).
The binding energy was estimated by introducing each experimentally
assessed point mutation in the 43,000 models, and measuring the energy of2384 Structure 23, 2377–2386, December 1, 2015 ª2015 Elsevier Ltdthe complex and of the receptor and ligand separately. To reduce the amount
of residues, which indirectly could affect ligand binding, we included only non-
proline and non-glycine residues. Likewise, to ensure that the receptor
remained functional, we discarded all receptor variants in which constitutive
activity was eliminated, unless they could still be activated by the ligand. We
required that the surface expression be at least 20% of the wild-type and
that the mutated residues were situated on the inside of the binding pocket
or in the loop region. These criteria left us with 28 point mutations in
GPR119 (Table 1). The correlation between the computed binding energies
and the experimentally determined binding energies was then determined
for each of the 43,000 binding conformations. The correlation was measured
as the SCC, a rank-based correlation score which, compared with the Pearson
correlation coefficient, is less sensitive to outliers. Finally, the models that
passed the filters described above and correlated better than 0.25 with the
experimental data were clustered (based on ligand binding conformation) in
bins of 2.5 A˚ RMSD using BCL::Cluster to quantitate the general trends in
the ensemble (Alexander et al., 2011).
Conformational Analysis of AR437735 and AR437948
The MMFF with a generalized Born solvation model was used to calculate the
difference in energy between axial and equatorial conformations of AR437735
and AR437948 using ICM 3.7-3 (Molsoft) with maximum number of conforma-
tions = 50, vicinity = 15, thoroughness = 10, and sample rings and Cartesian
refinement checked.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.str.2015.09.014.
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